Abstract
Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.
Similar content being viewed by others
References
Amari, A., M. Ebtekar, S.M. Moazzeni, M. Soleimani, L. Mohammadi Amirabad, M.T. Tahoori, and M. Massumi. 2015. In Vitro Generation of IL-35-expressing Human Wharton’s Jelly-derived Mesenchymal Stem Cells Using Lentiviral Vector. Iranian Journal of Allergy, Asthma, and Immunology 14(4): 416–426.
Aslam, R., Y. Hu, S. Gebremeskel, G.B. Segel, E.R. Speck, L. Guo, M. Kim, H. Ni, J. Freedman, and J.W. Semple. 2012. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood 120(10): 2127–2132. doi:10.1182/blood-2012-02-413526.
Baraut, J., L. Michel, F. Verrecchia, and D. Farge. 2010. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmunity Reviews 10(2): 65–73. doi:10.1016/j.autrev.2010.08.003.
Bryan, C., Y. Howard, P. Brennan, C. Black, and A. Silman. 1996. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. British Journal of Rheumatology 35(11): 1122–1126.
Cai, Z., C.K. Wong, J. Dong, M. Chu, D. Jiao, N.W. Kam, C.W. Lam, and L.S. Tam. 2015. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice. Clinical and Experimental Immunology 181(2): 253–266. doi:10.1111/cei.12639.
Collison, L.W., V. Chaturvedi, A.L. Henderson, P.R. Giacomin, C. Guy, J. Bankoti, D. Finkelstein, et al. 2010. IL-35-mediated induction of a potent regulatory T cell population. Nature Immunology 11(12): 1093–1101. doi:10.1038/ni.1952.
Collison, L.W., G.M. Delgoffe, C.S. Guy, K.M. Vignali, V. Chaturvedi, D. Fairweather, A.R. Satoskar, et al. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology 13(3): 290–299. doi:10.1038/ni.2227.
Collison, L.W., and D.A.A. Vignali. 2008. Interleukin-35: odd one out or part of the family? Immunological Reviews 226: 248–262.
Collison, L.W., C.J. Workman, T.T. Kuo, K. Boyd, Y. Wang, K.M. Vignali, R. Cross, D. Sehy, R.S. Blumberg, and D.A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169): 566–569. doi:10.1038/nature06306.
Dantas, A.T., S.M. Goncalves, M.C. Pereira, R.S. Goncalves, C.D. Marques, M.J. Rego, R. Pitta Ida, A.L. Duarte, and M.G. Pitta. 2015. Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement. Clinical Rheumatology 34(9): 1621–1625. doi:10.1007/s10067-015-3006-y.
Delgoffe, G.M., P.J. Murray, and D.A. Vignali. 2011. Interpreting mixed signals: the cell’s cytokine conundrum. Current Opinion in Immunology 23(5): 632–638. doi:10.1016/j.coi.2011.07.013.
Dieker, J., L. Hilbrands, A. Thielen, H. Dijkman, J.H. Berden, and J. van der Vlag. 2015. Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice. Arthritis Research and Therapy 17: 103. doi:10.1186/s13075-015-0617-2.
Egwuagu, C.E., C.R. Yu, L. Sun, and R. Wang. 2015. Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases. Cytokine and Growth Factor Reviews 26(5): 587–593. doi:10.1016/j.cytogfr.2015.07.013.
Fonseca-Camarillo, G., J. Furuzawa-Carballeda, and J.K. Yamamoto-Furusho. 2015. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine 75(2): 389–402. doi:10.1016/j.cyto.2015.04.009.
Giovannetti, Antonello, Edoardo Rosato, Cristina Renzi, Angela Maselli, Lucrezia Gambardella, Anna Maria Giammarioli, Paolo Palange, et al. 2010. Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Clinical Immunology 137(1): 122–133. doi:10.1016/j.clim.2010.06.004.
Hunter, C.A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nature Reviews Immunology 5(7): 521–531. doi:10.1038/nri1648.
Jiang, N., M. Li, and X. Zeng. 2014. Correlation of Th17 cells and CD4(+)CD25(+) regulatory T cells with clinical parameters in patients with systemic sclerosis. Chinese Medical Journal 127(20): 3557–3561.
Jones, L.L., and D.A.A. Vignali. 2011. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunologic Research 51(1): 5–14. doi:10.1007/s12026-011-8209-y.
Kalampokis, I., A. Yoshizaki, and T. F. Tedder. 2013. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 15 Suppl 1:S1. doi:10.1186/ar3907 ar3907
Kochetkova, I., S. Golden, K. Holderness, G. Callis, and D.W. Pascual. 2010. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. Journal of Immunology 184(12): 7144–7153. doi:10.4049/jimmunol.0902739.
Kochetkova, I., T. Thornburg, G. Callis, K. Holderness, M. Maddaloni, and D.W. Pascual. 2014. Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27. Journal of Immunology 192(2): 804–816. doi:10.4049/jimmunol.1302018.
Koutsokeras, T., and T. Healy. 2014. Systemic lupus erythematosus and lupus nephritis. Nature Reviews Drug Discovery 13(3): 173–174. doi:10.1038/nrd4227.
Langrish, C.L., B.S. McKenzie, N.J. Wilson, R. de Waal Malefyt, R.A. Kastelein, and D.J. Cua. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunology Reviews 202: 96–105. doi:10.1111/j.0105-2896.2004.00214.x.
Lee, S.Y., S.H. Lee, E.J. Yang, E.K. Kim, J.K. Kim, D.Y. Shin, and M.L. Cho. 2015. Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. PloS One 10(9), e0135858. doi:10.1371/journal.pone.0135858.
Leng, R.X., H.F. Pan, G.M. Chen, C. Wang, W.Z. Qin, L.L. Chen, J.H. Tao, and D.Q. Ye. 2010. IL-23: a promising therapeutic target for systemic lupus erythematosus. Archives of Medical Research 41(3): 221–225. doi:10.1016/j.arcmed.2010.02.011.
LeRoy, E.C., C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T.A. Medsger Jr., N. Rowell, and F. Wollheim. 1988. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. Journal of Rheumatology 15(2): 202–205.
Li, Y., X. Pan, X. Peng, S. Li, Y. Zhou, X. Zheng, and M. Li. 2015. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma. Inflammation Research 64(10): 767–774. doi:10.1007/s00011-015-0858-1.
Li, Y., Y. Wang, Y. Liu, X. Zuo, and X. Lu. 2014. The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease. Mediators of Inflammation 2014: 136329. doi:10.1155/2014/136329.
Li, Y., S. Wu, S. Jiang, T. Lin, L. Xia, H. Shen, and J. Lu. 2016. Interleukin-35 (IL-35) inhibits proliferation and promotes apoptosis of fibroblast-like synoviocytes isolated from mice with collagen-induced arthritis. Molecular Biology Reports 43(9): 947–956. doi:10.1007/s11033-016-4034-7.
Lim, J.Y., K.I. Im, E.S. Lee, N. Kim, Y.S. Nam, Y.W. Jeon, and S.G. Cho. 2016. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis. Science Reports 6: 26851. doi:10.1038/srep26851.
Liu, B., H. Zhao, M.C. Poon, Z. Han, D. Gu, M. Xu, H. Jia, R. Yang, and Z.C. Han. 2007. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. European Journal of Haematology 78(2): 139–143. doi:10.1111/j.1600-0609.2006.00780.x.
Ma, X., and G. Trinchieri. 2001. Regulation of interleukin-12 production in antigen-presenting cells. Advances in Immunology 79: 55–92.
Mauri, C., and K. Nistala. 2014. Interleukin-35 takes the ‘B’ line. Nature Medicine 20(6): 580–581. doi:10.1038/nm.3594.
McInnes, I.B., and G. Schett. 2011. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine 365(23): 2205–2219. doi:10.1056/NEJMra1004965.
McNamee, E.N., J.C. Masterson, M. Veny, C.B. Collins, P. Jedlicka, F.R. Byrne, G.Y. Ng, and J. Rivera-Nieves. 2015. Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn’s-like murine ileitis. Journal of Leukocyte Biology 97(6): 1011–1022. doi:10.1189/jlb.3HI0614-303R.
Mirshafiey, A., and M. Mohsenzadegan. 2009. TGF-beta as a promising option in the treatment of multiple sclerosis. Neuropharmacology 56(6–7): 929–936.
Mok, C.C., and C.S. Lau. 2003. Pathogenesis of systemic lupus erythematosus. Journal of Clinical Pathology 56(7): 481–490.
Nakano, S., S. Morimoto, S. Suzuki, H. Tsushima, K. Yamanaka, I. Sekigawa, and Y. Takasaki. 2015. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford) 54(8): 1498–1506. doi:10.1093/rheumatology/keu528.
Niedbala, W., X.Q. Wei, B. Cai, A.J. Hueber, B.P. Leung, I.B. McInnes, and F.Y. Liew. 2007. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European Journal of Immunology 37(11): 3021–3029. doi:10.1002/eji.200737810.
Ning-Wei, Z. 2010. Interleukin (IL)-35 is raising our expectations. Revista Medica De Chile 138(6): 758–766.
Niu, Q., B. Cai, Z.C. Huang, Y.Y. Shi, and L.L. Wang. 2012. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatology International 32(9): 2731–2736. doi:10.1007/s00296-011-1984-x.
O’Shea, J.J., and W.E. Paul. 2002. Regulation of T(H)1 differentiation—controlling the controllers. Nature Immunology 3(6): 506–508. doi:10.1038/ni0602-506.
Olsson, B., P.O. Andersson, M. Jernas, S. Jacobsson, B. Carlsson, L.M. Carlsson, and H. Wadenvik. 2003. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Medicine 9(9): 1123–1124. doi:10.1038/nm921.
Pan, H.F., J.H. Tao, and D.Q. Ye. 2010. Therapeutic potential of IL-27 in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets 14(5): 479–484. doi:10.1517/14728221003769911.
Pan, Hai-Feng, Xiang-Pei Li, Song Guo Zheng, and Dong-Qing Ye. 2013. Emerging role of interleukin-22 in autoimmune diseases. Cytokine & Growth Factor Reviews 24(1): 51–57. doi:10.1016/j.cytogfr.2012.07.002.
Pittenger, M.F., A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, and D.R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411): 143–147.
Podolsky, D.K. 2002. Inflammatory bowel disease. New England Journal of Medicine 347(6): 417–429. doi:10.1056/NEJMra020831.
Rasmusson, I., O. Ringden, B. Sundberg, and K. Le Blanc. 2003. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76(8): 1208–1213. doi:10.1097/01.TP.0000082540.43730.80.
Renner, K., F.J. Hermann, K. Schmidbauer, Y. Talke, M. Rodriguez Gomez, G. Schiechl, J. Schlossmann, H. Bruhl, H.J. Anders, and M. Mack. 2015. IL-3 contributes to development of lupus nephritis in MRL/lpr mice. Kidney International 88(5): 1088–1098. doi:10.1038/ki.2015.196.
Rubio-Rivas, M., C. Royo, C.P. Simeon, X. Corbella, and V. Fonollosa. 2014. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 44(2): 208–219. doi:10.1016/j.semarthrit.2014.05.010.
Sakakura, M., H. Wada, I. Tawara, T. Nobori, T. Sugiyama, N. Sagawa, and H. Shiku. 2007. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thrombosis Research 120(2): 187–193. doi:10.1016/j.thromres.2006.09.008.
Semple, J.W. 2002. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Reviews 16(1): 9–12. doi:10.1054/blre.2001.0172.
Shen, P., T. Roch, V. Lampropoulou, R.A. O’Connor, U. Stervbo, E. Hilgenberg, S. Ries, et al. 2014. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507(7492): 366–370. doi:10.1038/nature12979.
Shimomatsu, T., N. Kanazawa, N. Mikita, Y. Nakatani, H. J. Li, Y. Inaba, T. Ikeda, T. Kondo, and F. Furukawa. 2016. The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice. Modern Rheumatology:1–5. doi:10.3109/14397595.2016.1140711
Talaat, R.M., S.F. Mohamed, I.H. Bassyouni, and A.A. Raouf. 2015. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine 72(2): 146–153. doi:10.1016/j.cyto.2014.12.027.
Toriani-Terenzi, C., and E. Fagiolo. 2005. IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia. Annals of the New York Academy of Sciences 1051: 29–44. doi:10.1196/annals.1361.044.
Wang, R.X., C.R. Yu, I.M. Dambuza, R.M. Mahdi, M.B. Dolinska, Y.V. Sergeev, P.T. Wingfield, S.H. Kim, and C.E. Egwuagu. 2014. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nature Medicine 20(6): 633–641. doi:10.1038/nm.3554.
Wang, W., S. Shao, Z. Jiao, M. Guo, H. Xu, and S. Wang. 2012. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatology International 32(4): 887–893. doi:10.1007/s00296-010-1710-0.
Whitehead, G.S., R.H. Wilson, K. Nakano, L.H. Burch, H. Nakano, and D.N. Cook. 2012. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. The Journal of Allergy and Clinical Immunology 129(1): 207–215. doi:10.1016/j.jaci.2011.08.009. e201-205.
Wirtz, S., U. Billmeier, T. McHedlidze, R.S. Blumberg, and M.F. Neurath. 2011. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 141(5): 1875–1886. doi:10.1053/j.gastro.2011.07.040.
Xavier, R.J., D.K. Podolsk, and D.K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152): 427–434. doi:10.1038/nature06005.
Yang, Y., M. Xuan, X. Zhang, D. Zhang, R. Fu, F. Zhou, L. Ma, et al. 2014. Decreased IL-35 levels in patients with immune thrombocytopenia. Human Immunology 75(8): 909–913. doi:10.1016/j.humimm.2014.06.019.
Yoshida, H., and Y. Miyazaki. 2008. Regulation of immune responses by interleukin-27. Immunology Reviews 226: 234–247. doi:10.1111/j.1600-065X.2008.00710.x.
Yoshimura, T., A. Takeda, S. Hamano, Y. Miyazaki, I. Kinjyo, T. Ishibashi, A. Yoshimura, and H. Yoshida. 2006. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. Journal of Immunology 177(8): 5377–5385.
Yu, J., S. Heck, V. Patel, J. Levan, Y. Yu, J.B. Bussel, and K. Yazdanbakhsh. 2008. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112(4): 1325–1328. doi:10.1182/blood-2008-01-135335.
Yu, S., C. Liu, L. Li, T. Tian, M. Wang, Y. Hu, C. Yuan, L. Zhang, C. Ji, and D. Ma. 2015. Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. Laboratory Investigation 95(2): 157–167. doi:10.1038/labinvest.2014.142.
Zhou, L., F. Xu, C. Chang, Y. Tao, L. Song, and X. Li. 2016. Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia. Blood Coagulation and Fibrinolysis 27(3): 301–307. doi:10.1097/MBC.0000000000000423.
Zhou, X., N. Kong, H. Zou, D. Brand, X. Li, Z. Liu, and S.G. Zheng. 2011. Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity 44(1): 43–50. doi:10.3109/08916931003782163.
Zhu, M., H. Mo, D. Li, X. Luo, and L. Zhang. 2013. Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with systemic lupus erythematosus (SLE). Clinical Rheumatology 32(7): 1045–1052. doi:10.1007/s10067-013-2237-z.
Acknowledgment
This work was supported by grants from the National Natural Science Foundation of China (81573222).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Guan, SY., Leng, RX., Khan, M.I. et al. Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases. Inflammation 40, 303–310 (2017). https://doi.org/10.1007/s10753-016-0453-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-016-0453-9